top of page

Barclays Miami: Janux's Founder & CEO David Campbell shares his thoughts on the company's PSMA x CD3 masked T-cell engager and discusses next steps. Plus, a CD19 for autoimmune

  • Mar 10
  • 1 min read

He shares highlights from data announced at the end of the year, and what Janux has learned about the program's dosing and safety mitigation profile. Also, why he has his sights set on the FcRn market when he thinks about the company's CD19.






Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page